Compare McCormick & Company, Incorporated (MKC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Zimmer Biomet Holdings Inc — how do they compare? McCormick & Company, Incorporated trades at $46 (market cap $12.39B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and McCormick & Company, Incorporated pays the higher dividend (4.18%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MKC | ZBH | |
|---|---|---|
Market Cap | $12.39B | $16.95B |
Volume | 6,140,872 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $103.98 |
52-Week Low | $44.14 | $79.58 |
Typical Hold Time | 67 Days | 89 Days |
Enterprise Value | $17.07B | $24.02B |
Dividend Yield | 4.18% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $45.25, down 0.33% with a bearish technical signal despite strong Q3 2026 earnings that beat estimates. The stock shows attractive valuation metrics with a P/E of 8.18 and robust profitability including 19.39% net income margin. Recent performance reflects 17% sales growth driven by the Mexico acquisition and margin expansion, though technical indicators suggest near-term pressure with support at $44.
MKC presents a compelling value opportunity with below-sector P/E ratio and consistent dividend payments, though bearish technicals and mixed analyst sentiment (33% buy, 60% hold) indicate caution. Upside potential exists to the $53.50 consensus target, but investors face risks from integration challenges and macroeconomic pressure on consumer spending.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
